The goal is to develop a treatment for 'T-cell derived hematologic malignancies,' a rare and currently incurable disease
[by Ji, Yong Jun] Curocell, a company specializing in chimeric antigen receptor T-cell (CAR-T) treatments, announced on April 14 that it will present preclinical study data on its T-cell-derived hematologic malignancies ‘allogeneic CAR-T treatment’ at the ‘American Association for Cancer Research (AACR) 2025 Annual Meeting.’ The event is scheduled to take place in Chicago, USA, from April 25 to 30 (local time).
‘T-cell-derived hematologic malignancies,’ such as T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphoma (PTCL), are characterized by limited treatment options and high relapse rates, underscoring the urgent need for novel treatments. In this context, 피망 바카라 cell therapy has been attracting attention, but conventional ‘autologous 피망 바카라 treatments,’ which rely on patients’ own T cells, face significant challenges like risks of fratricide or tumor cell contamination, thereby hindering their clinical development.
To address these challenges, Curocell has concentrated its efforts on developing an allogeneic 피망 바카라 treatment using T cells derived from ‘healthy donors.’ According to the abstract published in advance of the AACR presentation, the company reported that its allogeneic 피망 바카라 therapeutic candidate, ‘CD5 gammadelta (γδ) 피망 바카라,’ developed with their latest technology, demonstrated potent anticancer efficacy.
CD5 γδ 피망 바카라 cells exhibited over a tenfold increase in proliferation capacity compared to conventional 피망 바카라 cells through the incorporation of membrane-bound IL-18 (mbIL-18) technology into allogeneic T-cells. Furthermore, the candidate demonstrated strong anticancer efficacy in a T-ALL xenograft model. Notably, the simultaneous knockout of CD5 and PD-1 genes effectively mitigated fratricide among 피망 바카라 cells and overcame immune suppression in the tumor microenvironment, thereby enhancing overall therapeutic efficacy.
Curocell highlighted that its multi-faceted enhancement strategy represents an innovative approach that addresses the inherent limitations of existing autologous 피망 바카라 therapies while broadening the therapeutic potential of allogeneic 피망 바카라 treatments for T cell-derived hematologic malignancies. In particular, the company emphasized that the preclinical study results will serve as a foundation for accelerating the development of T-cell-derived hematologic malignancies treatment following Curocell’s next-generation 피망 바카라 therapy, ‘RIMQARTO,’ which is currently undergoing the health insurance reimbursement listing process.
“Allogeneic CAR-T treatment is attracting attention as a next-generation anticancer immunotherapy capable of overcoming the limitations of conventional autologous CAR-T treatments,” said Kim Gun-soo, CEO of Curocell. “By leveraging our differentiated CAR-T technology, we aim to maximize the scalability and efficacy of allogeneic treatments. Building on this foundation, we are committed to advancing treatment for T-cell-derived hematologic malignancies, where therapeutic options remain limited, and establishing ourselves as a global leader in anticancer immunotherapy.”